Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₩57,800, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 7x in the Medical Equipment industry in South Korea. Total returns to shareholders of 97% over the past three years. Board Change • Jun 26
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Full-Time Auditor HeeJung Kim was the last director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩45,550, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 8x in the Medical Equipment industry in South Korea. Total returns to shareholders of 62% over the past three years. New Risk • Jun 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • May 08
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to ₩38,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 49% over the past three years. Reported Earnings • Mar 24
Full year 2025 earnings: Revenues and EPS in line with analyst expectations Full year 2025 results: EPS: ₩2,423 (down from ₩2,557 in FY 2024). Revenue: ₩233.9b (up 14% from FY 2024). Net income: ₩30.6b (down 7.6% from FY 2024). Profit margin: 13% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 31% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has remained flat. Upcoming Dividend • Mar 23
Upcoming dividend of ₩600 per share Eligible shareholders must have bought the stock before 30 March 2026. Payment date: 17 April 2026. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.2%). Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩28,650, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 2.3% over the past three years. Declared Dividend • Mar 01
Dividend increased to ₩600 Dividend of ₩600 is 50% higher than last year. Ex-date: 30th March 2026 Payment date: 17th April 2026 Dividend yield will be 1.9%, which is higher than the industry average of 1.8%. Sustainability & Growth Dividend is well covered by both earnings (15% earnings payout ratio) and cash flows (25% cash payout ratio). The dividend has increased by an average of 19% per year over the past 7 years and payments have been stable during that time. EPS is expected to grow by 32% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Price Target Changed • Feb 28
Price target increased by 29% to ₩45,000 Up from ₩35,000, the current price target is provided by 1 analyst. New target price is 41% above last closing price of ₩32,000. Stock is up 36% over the past year. The company is forecast to post earnings per share of ₩2,404 for next year compared to ₩2,557 last year. Announcement • Feb 27
InBody Co.,Ltd announces Annual dividend, payable on April 17, 2026 InBody Co.,Ltd announced Annual dividend of KRW 600.0000 per share payable on April 17, 2026, ex-date on March 30, 2026 and record date on March 31, 2026. Announcement • Feb 20
InBody Co.,Ltd to Report Q4, 2025 Results on Feb 26, 2026 InBody Co.,Ltd announced that they will report Q4, 2025 results on Feb 26, 2026 New Risk • Aug 30
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2012. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company. Price Target Changed • Aug 15
Price target increased by 7.2% to ₩37,000 Up from ₩34,500, the current price target is provided by 1 analyst. New target price is 31% above last closing price of ₩28,250. Stock is up 14% over the past year. The company is forecast to post earnings per share of ₩2,404 for next year compared to ₩2,557 last year. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩28,300, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 15% over the past three years. Major Estimate Revision • May 23
Consensus EPS estimates fall by 13% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩2,670 to ₩2,336 per share. Revenue forecast steady at ₩233.1m. Net income forecast to shrink 4.7% next year vs 43% growth forecast for Medical Equipment industry in South Korea . Consensus price target of ₩35,000 unchanged from last update. Share price rose 5.9% to ₩25,000 over the past week. Announcement • Apr 08
InBody Co.,Ltd (KOSDAQ:A041830) announces an Equity Buyback for KRW 10,000 million worth of its shares. InBody Co.,Ltd (KOSDAQ:A041830) announces a share repurchase program. Under the program, the company will repurchase up to KRW 10,000 million worth of its shares, pursuant to a contract with Shinhan Investment & Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on October 7, 2025. As of April 7, 2025, the company had 872,935 shares in treasury within scope available for dividend and had no shares in treasury under other capacities. Reported Earnings • Mar 21
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: ₩2,557 (down from ₩2,819 in FY 2023). Revenue: ₩204.5b (up 20% from FY 2023). Net income: ₩33.1b (down 9.7% from FY 2023). Profit margin: 16% (down from 22% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 4.7%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Upcoming Dividend • Mar 21
Upcoming dividend of ₩400 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 15 April 2025. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.3%). Major Estimate Revision • Feb 22
Consensus EPS estimates fall by 12%, revenue upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from ₩228.6m to ₩231.0m. EPS estimate fell from ₩3,041 to ₩2,670 per share. Net income forecast to grow 13% next year vs 42% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩35,000 unchanged from last update. Share price rose 5.6% to ₩25,600 over the past week. Announcement • Feb 22
InBody Co.,Ltd announces Annual dividend, payable on April 15, 2025 InBody Co.,Ltd announced Annual dividend of KRW 400.0000 per share payable on April 15, 2025, ex-date on March 28, 2025 and record date on March 31, 2025. Announcement • Feb 21
InBody Co.,Ltd, Annual General Meeting, Mar 25, 2025 InBody Co.,Ltd, Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 625, eonju-ro, gangnam-gu, seoul South Korea Announcement • Feb 19
InBody Co.,Ltd to Report Q4, 2024 Results on Feb 20, 2025 InBody Co.,Ltd announced that they will report Q4, 2024 results on Feb 20, 2025 New Risk • Dec 09
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company. Announcement • Nov 18
InBody Co.,Ltd (KOSDAQ:A041830) announces an Equity Buyback for KRW 5,000 million worth of its shares. InBody Co.,Ltd (KOSDAQ:A041830) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a contract with Shinhan Investment & Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on May 19, 2025. As of November 17, 2024, the company had 857,335 shares in treasury within scope available for dividend and had no shares in treasury under other capacities. Announcement • Aug 26
InBody Co.,Ltd (KOSDAQ:A041830) announces an Equity Buyback for KRW 5,000 million worth of its shares. InBody Co.,Ltd (KOSDAQ:A041830) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a contract with Shinhan Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on February 25, 2025. As of August 25, 2024, the company had 656,935 shares in treasury within scope available for dividend and had no shares in treasury under other capacities. Reported Earnings • Mar 20
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: ₩2,819 (up from ₩2,596 in FY 2022). Revenue: ₩170.4b (up 6.5% from FY 2022). Net income: ₩36.7b (up 8.6% from FY 2022). Profit margin: 22% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.9%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 14% per year and the company’s share price has also increased by 14% per year. Upcoming Dividend • Dec 20
Upcoming dividend of ₩300 per share at 1.2% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%). Reported Earnings • Mar 19
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Full year 2022 results: EPS: ₩2,596 (down from ₩2,613 in FY 2021). Revenue: ₩160.0b (up 16% from FY 2021). Net income: ₩33.8b (flat on FY 2021). Profit margin: 21% (down from 25% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 7.0% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 01
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩29,000, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 46% over the past three years. Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩26,000, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 26% over the past three years. Upcoming Dividend • Dec 21
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 18 April 2023. Payout ratio is a comfortable 7.1% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.8%). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Jun 30
InBody Releases BPBIO 220 and BPBIO 250 InBody announced the release of two new professional-grade blood pressure monitors, the BPBIO 220 and the BPBIO 250. The BPBIO 220 and BPBIO 250 are part of a new generation of blood pressure devices that meet updated mercury-free standards for use within the medical field. While the use of mercury in blood pressure monitors has been an industry gold standard for years, a number of independent research studies have raised concerns regarding the safety of mercury, its use in the workplace, and human error that could be associated with manually measuring this data. To alleviate these concerns, the BPBIO 220 was designed to help the clinician accurately measure individual blood pressure manually using the auscultatory method. With the patented controller, it helps eliminate errors by allowing clinicians to conveniently mark blood pressure and control exhaust speed using one hand. Its automatic counterpart, the BPBIO 250, uses the oscillometric method to quantify patient health and is equipped with a patented one-touch cuff to improve user comfort and five different test modes, including auscultatory mode, which allow clinicians to optimize measurements according to test environment and individual patient condition. In addition, the BPBIO 250 also comes with additional accessories, such as a rechargeable lithium ion battery, cuff rack and curl cable for easy storage, and Bluetooth capabilities. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Apr 03
Inbody Co.,Ltd Releases New Bwa 2.0 Body Water Analyzer InBody Co.,Ltd announced the release of its BWA 2.0 body water analyzer. This new professional-grade device expands upon the outputs measured by the InBody S10 to provide users with more detailed insights that demonstrate how variations in body composition and body water can affect wellbeing. With this launch, InBody is showcasing how body water is the foundation upon which all other BIA measurements are built. Body water has a major influence on readings provided by BIA devices because body composition is measured by sending electrical currents through the body to measure impedance. Since most body water is stored within muscles, outputs for lean mass and body water are directly correlated. Similar to its predecessor, the InBody S10, the portable, convenient design of the BWA 2.0 allows for on-the-go testing to be performed in Medical Mode or Research Mode. Additionally, users can also choose to test in a supine, seated, or standing position, giving individuals with limited mobility or amputated limbs equal access to accurate measurements for standard outputs like percentage body fat and skeletal muscle mass. Plus, using 8 different frequencies, 40 impedance measurements will be taken across the five segments of the body. Because of this, the device is capable of measuring more outputs and can print up to seven separate results sheets that summarize: Body Water Results; Body Composition Results; Body Composition Results for Children; Research Results; Evaluation Results; Comparison Results; and Thermal Results. Upcoming Dividend • Dec 22
Upcoming dividend of ₩140 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 06 April 2022. Payout ratio is a comfortable 5.7% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (2.4%). In line with average of industry peers (0.7%). Price Target Changed • May 16
Price target increased to ₩34,000 Up from ₩25,500, the current price target is provided by 1 analyst. New target price is 33% above last closing price of ₩25,650. Stock is up 34% over the past year. Valuation Update With 7 Day Price Move • May 12
Investor sentiment improved over the past week After last week's 27% share price gain to ₩26,000, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 29% over the past three years. Reported Earnings • Mar 21
Full year 2020 earnings released: EPS ₩1,335 (vs ₩1,532 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩107.1b (down 8.5% from FY 2019). Net income: ₩17.5b (down 14% from FY 2019). Profit margin: 16% (down from 18% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Feb 18
New 90-day high: ₩19,600 The company is up 12% from its price of ₩17,500 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 25
New 90-day high: ₩19,200 The company is up 26% from its price of ₩15,200 on 27 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 13% over the same period. Is New 90 Day High Low • Jan 06
New 90-day high: ₩18,500 The company is up 15% from its price of ₩16,100 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 5.0% over the same period. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩140 Per Share Will be paid on the 16th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.8% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.7%). Is New 90 Day High Low • Dec 04
New 90-day high: ₩18,300 The company is up 14% from its price of ₩16,050 on 04 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩23,842 per share. Is New 90 Day High Low • Nov 17
New 90-day high: ₩17,450 The company is up 8.0% from its price of ₩16,200 on 19 August 2020. The South Korean market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩23,279 per share. Is New 90 Day High Low • Oct 22
New 90-day low: ₩15,300 The company is down 7.0% from its price of ₩16,400 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩29,048 per share. 
